Top payer group shoots down Gilead's hep C drug Sovaldi on price

Gilead's Sovaldi--Courtesy of Gilead

Individual payers aren't alone in balking at the $84,000 price for Gilead Sciences' ($GILD) new hepatitis C treatment Sovaldi. Now, the leading insurance trade group has joined the soloists, backing their complaints with its own. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.